Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, a Fully Human Anti-TNFalpha Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Golimumab, a Fully Human Anti-TNFalpha Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Ankylosing Spondylitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms GO-RAISE
  • Sponsors Centocor
  • Most Recent Events

    • 08 Nov 2018 Results of a pooled analysis from GO-RAISE, GO-FORWARD, GO-REVEAL studies published in the Rheumatology .
    • 17 Jun 2017 Results assessing the comparative effectiveness of Secukinumab and Golimumab up to week 24 using patient data from GO-RAISE, MEASURE 1, MEASURE 2 trials, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 01 Nov 2016 Results of 5-year safety data from five trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-REVEAL, GO-RAISE) published in The Journal of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top